Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Core Insights - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1][2] - CEO Andrew Obenshain will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026, in New York City [1][2] Company Overview - Inventiva is engaged in the research and development of oral small molecule therapies targeting MASH and other diseases with significant unmet medical needs [2] - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for adult patients with MASH [2] Stock Information - Inventiva is publicly listed on Euronext Paris (ticker: IVA) and the Nasdaq Global Market in the United States (ticker: IVA) [3]